JP2016520077A - Ｅ１ｅ２ｈｃｖワクチン及び使用方法 - Google Patents

Ｅ１ｅ２ｈｃｖワクチン及び使用方法 Download PDF

Info

Publication number
JP2016520077A
JP2016520077A JP2016513459A JP2016513459A JP2016520077A JP 2016520077 A JP2016520077 A JP 2016520077A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016520077 A JP2016520077 A JP 2016520077A
Authority
JP
Japan
Prior art keywords
polypeptide
hcv
hcv genotype
genotype
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016513459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520077A5 (enExample
Inventor
マイケル ホートン
マイケル ホートン
ダレン ホックマン
ダレン ホックマン
ジョン エル． ロウ
ジョン エル． ロウ
マイケル ローガン
マイケル ローガン
ロルネ ディー． ティレル
ロルネ ディー． ティレル
Original Assignee
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ, ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ filed Critical ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
Publication of JP2016520077A publication Critical patent/JP2016520077A/ja
Publication of JP2016520077A5 publication Critical patent/JP2016520077A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016513459A 2013-05-15 2014-05-15 Ｅ１ｅ２ｈｃｖワクチン及び使用方法 Withdrawn JP2016520077A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087976A Division JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Publications (2)

Publication Number Publication Date
JP2016520077A true JP2016520077A (ja) 2016-07-11
JP2016520077A5 JP2016520077A5 (enExample) 2017-06-22

Family

ID=54054625

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016513459A Withdrawn JP2016520077A (ja) 2013-05-15 2014-05-15 Ｅ１ｅ２ｈｃｖワクチン及び使用方法
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Country Status (8)

Country Link
US (3) US20210145963A9 (enExample)
EP (2) EP2996718B1 (enExample)
JP (5) JP2016520077A (enExample)
CN (2) CN105263517B (enExample)
AU (3) AU2014385320B2 (enExample)
CA (1) CA2909586C (enExample)
CL (1) CL2015003333A1 (enExample)
WO (1) WO2015132619A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060857A1 (en) * 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
CN109963587A (zh) * 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
CN110381996A (zh) * 2016-10-11 2019-10-25 艾伯塔大学理事会 包含环状二核苷酸或古细菌脂质体作为佐剂的丙型肝炎病毒免疫原性组合物及其使用方法
AU2019233861A1 (en) 2018-03-16 2020-10-01 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502611A (ja) * 2001-06-29 2005-01-27 カイロン コーポレイション Ｈｃｖｅ１ｅ２ワクチン組成物
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
PT773957E (pt) 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
ATE437951T1 (de) 1997-05-06 2009-08-15 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502611A (ja) * 2001-06-29 2005-01-27 カイロン コーポレイション Ｈｃｖｅ１ｅ２ワクチン組成物
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＡＮＴＩＶＩＲＡＬ ＴＨＥＲＡＰＹ, vol. 11, no. 8, JPN6018007756, 2006, pages 1005 - 1014, ISSN: 0004104496 *
ＧＡＳＴＲＯＥＮＴＥＲＯＬＯＧＹ, vol. [online], JPN6018007754, 11 May 2013 (2013-05-11), pages 10 - 1053, ISSN: 0004104494 *
ＪＯＵＲＮＡＬ ＯＦ ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥＳ, vol. 204, no. 8, JPN6018007758, 2011, pages 1186 - 1190, ISSN: 0003752961 *
ＰＬＯＳ ＯＮＥ, vol. Ｖｏｌ．８，Ｎｏ．３，ｅ５９７７６, JPN6018007746, March 2013 (2013-03-01), pages 1 - 7, ISSN: 0004104492 *
ＰＲＯＣ．ＮＡＴＬ．ＡＣＡＤ．ＳＣＩ．ＵＳＡ, vol. 102, no. 12, JPN6019033403, March 2005 (2005-03-01), pages 4560 - 4565, ISSN: 0004104497 *
ＶＡＣＣＩＮＥ, vol. 28, no. 38, JPN6018007750, 2010, pages 6367 - 6373, ISSN: 0004104493 *
ＶＡＣＣＩＮＥ, vol. 29, no. 16, JPN6018007761, 2011, pages 2910 - 2917, ISSN: 0004104495 *

Also Published As

Publication number Publication date
US20240316186A1 (en) 2024-09-26
CN105263517B (zh) 2021-03-26
EP3689375A1 (en) 2020-08-05
CN105263517A (zh) 2016-01-20
US20210145963A9 (en) 2021-05-20
JP2021059596A (ja) 2021-04-15
AU2022200747A1 (en) 2022-02-24
CL2015003333A1 (es) 2016-09-30
JP2024156917A (ja) 2024-11-06
CA2909586C (en) 2021-08-31
US20230098265A1 (en) 2023-03-30
CA2909586A1 (en) 2015-09-11
AU2014385320B2 (en) 2019-10-10
AU2014385320A1 (en) 2015-11-12
EP2996718A1 (en) 2016-03-23
EP2996718B1 (en) 2020-01-15
US20160067332A1 (en) 2016-03-10
JP2022172244A (ja) 2022-11-15
AU2020200216A1 (en) 2020-02-06
CN112999344A (zh) 2021-06-22
EP2996718A4 (en) 2017-06-21
HK1216395A1 (en) 2016-11-11
JP2019142962A (ja) 2019-08-29
WO2015132619A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
US20240316186A1 (en) E1e2 hcv vaccines and methods of use
US12202859B2 (en) Hepatitis c virus E1/E2 heterodimers and methods of producing same
US12005116B2 (en) Hepatitis C virus immunogenic compositions and methods of use thereof
WO2014060851A2 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1216395B (en) E1e2 hcv vaccines and methods of use
HK40120034A (en) Hepatitis c virus e1/e2 heterodimers and methods of producing same
HK40121294A (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1255379B (en) Hepatitis c virus immunogenic compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190716

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190830

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200121